The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2019 | Immunotoxicity in advanced lung cancer: how does this influence future practice?

Name: Immunotoxicity in advanced lung cancer: how does this influence future practice?
Uploaded: 2019-01-24T00:00:00Z
Duration: 1 min 28 s
Description: Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, of the Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, discusses what lessons can be learnt from immunotoxicity in advanced lung cancer, and how this could influence future practice. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.

Tom Newsom-Davis • 24 Jan 2019

BTOG 2019

Lung Cancer Non-Small Cell Lung Cancer Durvalumab

PACIFIC

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, of the Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, discusses what lessons can be learnt from immunotoxicity in advanced lung cancer, and how this could influence future practice. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.